- Home
- MNDY vs ACLX Comparison
MNDY vs ACLX Comparison
Compare MNDY & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MNDY | ACLX |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4B | 6.7B |
| IPO Year | 2021 | 2022 |
Fundamental Metrics
Financial Performance| Metric | MNDY | ACLX |
|---|---|---|
| Price | $65.26 | $115.03 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 26 | 15 |
| Target Price | ★ $171.46 | $115.85 |
| AVG Volume (30 Days) | ★ 1.4M | 1.0M |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $22,286,000.00 |
| Revenue This Year | $20.70 | $411.22 |
| Revenue Next Year | $16.48 | $138.37 |
| P/E Ratio | $34.38 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $57.50 | $47.86 |
| 52 Week High | $316.98 | $115.10 |
Technical Indicators
Market Signals| Indicator | MNDY | ACLX |
|---|---|---|
| Relative Strength Index (RSI) | 41.65 | 81.29 |
| Support Level | N/A | $66.06 |
| Resistance Level | $80.58 | N/A |
| Average True Range (ATR) | 3.35 | 0.15 |
| MACD | 0.44 | -0.96 |
| Stochastic Oscillator | 58.59 | 86.61 |
Price Performance
Historical ComparisonAbout MNDY monday.com Ltd.
Monday.com is a work management platform allowing for increased collaboration and visibility across an organization. Delivered via a SaaS-based model, users can track progress across marketing and development initiatives, create and automate workflows, and manage IT approvals. Revenue is generated on a per-seat basis across several pricing tiers. As of fiscal 2024, the company had over 245,000 customers.
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.